drugset / Trial / NCT04820907

Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

NCT04820907

Phase 3 Completed 123 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate of efficacy and safety of HCP1904-1 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.

Timeline

Start
2020-10-27
Primary completion
2021-09-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1904-1 Unknown Oral
Comparator RLD2001-1 Unknown Oral